GREENWICH, Conn., March 03, 2025 (GLOBE NEWSWIRE) — Gabelli Funds is hosting its 16th Annual Specialty Chemicals Symposium taking place at The Harvard Club in New York, NY on Thursday, March 20, 2025.  The symposium will draw a variety of companies, with a focus on pricing power, margin recovery, interest rates, inventory stabilization, global trade policy, demand trends, and the M&A environment.  Attendees will also have the opportunity to meet with managements in a one-on-one setting. Agenda:8:20am Opening Remarks Rosemarie Morbelli, CFA Gabelli Funds    Wayne Pinsent, CFA Gabelli Funds     8:30 Cabot Corporation (NYSE: CBT)* To Be Confirmed          9:00 Arq, Inc. (NASDAQ: ARQ) Bob Rasmus, President & CEO          9:30 BASF Corporation (XETRA: BAS.DE) Alex Koehler, Investor Relations          10:00 American...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s fourth quarter 2024 financial results on Monday, March 10, 2025, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus infection,...

GEORGE TOWN, Cayman Islands, March 03, 2025 (GLOBE NEWSWIRE) — Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water supply and treatment plants, has been invited to attend the 37th Annual ROTH Conference being held at The Laguna Cliffs Marriott in Dana Point, California, on March 16-18, 2025.The conference will feature on-demand presentations by companies across a range of industry sectors, in-person one-on-one and small group meetings, industry panels, and fireside chats. Past conferences have attracted more than 5,000 participants, comprised of institutional investors, family offices, high-net-worth investors, and equity analysts. On March 17-18, Consolidated Water CEO, Rick McTaggart, will participate in one-on-one meetings with analysts and investors....

ROGERS, Ark., March 03, 2025 (GLOBE NEWSWIRE) — America’s Car-Mart, Inc. (NASDAQ: CRMT) (“we,” “Car-Mart” or the “Company”), today announced that it has extended and upsized its asset-based revolving credit facility (“ABL Facility”). The $350 million ABL Facility was upsized from the prior $320 million commitment and has been extended to mature on March 31, 2027. There was approximately $75 million drawn on the ABL Facility as of January 31, 2025. The ABL Facility was subscribed by a syndicate of lenders with BMO Bank (“BMO”) as administrative agent. “Today’s announcement reflects the success of ongoing initiatives aimed at expanding our funding programs.   We were excited to be able to upsize the ABL Facility and expand the number of relationships in our bank group, with participation in the funding being oversubscribed. The combination...

SANTA CLARA, Calif., March 03, 2025 (GLOBE NEWSWIRE) — SiTime Corporation (Nasdaq: SITM), the Precision Timing company, today announced that SiTime’s CEO, Rajesh Vashist, and CFO, Beth Howe, will present at the Morgan Stanley Technology, Media & Telecom Conference to be held at the Palace Hotel in San Francisco, CA. SiTime management is scheduled to host a fireside chat at 4:50 p.m. PST on Tuesday, March 4, 2025. A live and archived webcast of the Company’s fireside chat will be available in the Events section of SiTime’s Investor Relations website. About SiTime SiTime Corporation is the Precision Timing company. Our semiconductor MEMS programmable solutions offer a rich feature set that enables customers to differentiate their products with higher performance, smaller size, lower power and better reliability. With more than...

VANCOUVER, British Columbia, March 03, 2025 (GLOBE NEWSWIRE) — Norden Crown Metals Corp. (“Norden Crown” or the “Company“) (TSXV:NOCR, Frankfurt; 03E) provides new assay results from reconnaissance mapping and sampling at the high-priority Sunrise Target at the Smart Creek Project located in western Montana, USA (Figure 1).   The discovery of Gold mineralization sampled at surface 850 meters from the Sunrise Mine substantially increases the discovery potential of this target. Summary of Results:New discovery of gold-rich porphyry intrusions (4.26 g/t gold) 850m east of the historic Sunrise Mine. New porphyry target at Sunrise where historical mining reported grades of 6.22 g/t Au, 31.1 g/t Ag and 1.5% Cu1,2,3. High gold tenor in samples (3.2 g/t and 4.2 g/t gold) from the historic Sunrise Mine area. Confirmed...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in TD Cowen’s 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference 2025. Details are as follows: TD Cowen 45th Annual Health Care ConferenceDate: Tuesday, March 4Time: 1:10 PM ET – 1:40 PM ETFormat: Company Presentation Leerink Partners Global Healthcare Conference 2025Date: Wednesday, March 12Time: 8:40 AM ET – 9:10 AM ETFormat: Fireside Chat The live and archived webcast of the presentation and fireside chat may be accessed from the Investors...

DURHAM, N.C., March 03, 2025 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced it will host an in-person and virtual investor event in New York on Thursday, March 6, 2025 at 12:00 PM ET. To register as an in-person or virtual attendee, please click here. The event will feature vascular surgery key opinion leaders (KOLs) Michael Curi, MD, MPA (Rutgers New Jersey Medical School) and Sammy Siada, DO, FACS, RPVI (UCSF Fresno), who will join company management to discuss the commercial plans and early market-launch success of Symvess (acellular tissue engineered vessel-tyod) for extremity arterial injury. Symvess is a first-in-class bioengineered human tissue designed to be a universally...

─Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)─ ─Achieved Alignment with FDA on Clear and Efficient Pathway to Potential Regulatory Approval for the Treatment of PSC with No Liver Biopsies or Confirmatory Studies Needed; Nebokitug Positioned to Potentially Become the First FDA-Approved Treatment for PSC─ ─On Track for Releasing Clinical Data from SPRING Trial Open Label Extension in First Quarter 2025─ ─Discussions with Potential Strategic Partners Ongoing─ TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) — Chemomab Therapeutics Ltd. (Nasdaq:CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the...

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. “Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid,” said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. “With our advancing pipeline, including our novel KCC2 direct activators and OV329 epilepsy program, Ovid stands on the cusp of delivering real change for neurological and psychiatric...